Home › mercks
 

Keywords :   


Tag: mercks

Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014

2014-04-06 16:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Exploratory Analyses in Advanced Melanoma and NSCLC Presented in Oral Session Dr. Roger Perlmutter to Present at AACR Opening Plenary Session WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early findings from studies exploring the relationship between tumor PD-L1 expression and clinical outcomes following monotherapy treatment with MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma and advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: early presented meeting annual

 

FDA Approves Merck's NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use

2014-03-15 04:54:54| Biotech - Topix.net

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL injection , a new formulation of NOXAFIL for intravenous use.

Tags: use injection fda approves

 
 

FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use

2014-03-14 18:40:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. Mercks antifungal agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension. Language: English Contact: MerckMedia:Pam Eisele, (267) 305-3558Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: use injection fda approves

 

Mercks Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection

2014-03-05 22:15:00| Merck.com - Research & Development News

Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orIan McConnell, 908-423-3046orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: shows activity treatment patients

 

Mercks Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Nave Adults

2014-03-05 18:15:00| Merck.com - Research & Development News

Dateline City: BOSTON Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the companys investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: study activity phase adults

 

Sites : [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »